Latest Stock Market News

Glenmark is ranked 14th with a market share of 2.17% Sales from North America fell 10.2% YoY to Rs 663 crore. Europe sales saw 8% YoY to Rs 330 crore, and the rest of the world rose 26% to Rs 423 crore.

After the sale, the LIC holding in the passenger cars and utility vehicles company decreased from 8.430 per cent to 6.421 per cent, it said.

Meanwhile, CP rates have increased by up to 50 basis points since the second-third weeks of July, amid a higher supply of papers coupled with expectations of more rate hikes by the central bank.

The asset under management (AUM) stood at Rs 73,047 crore and the lender expects a growth of around 10 per cent in the AUM during FY23. Shares of the company ended at Rs 123, down 1.44 per cent on BSE on Wednesday.

Its insurance premium grew 52 per cent YoY To Rs 2,430 crore, while credit disbursal grew 136 per cent YoY.

Being part of the globally integrated supply chain, the company is well-positioned to manage parts, supplies to mitigate the "impact" on revenue and profitability, Cummins India, an engine and related parts making company, said.

"We delivered a strong double digit growth in our base business during the quarter excluding the impact of COVID-related products," Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said in a regulatory filing.

“We delivered double-digit revenue growth and improved profitability for the company despite a challenging macro environment and inflation impact in some of our categories," said Sunil D’Souza, Managing Director & CEO of Tata Consumer Products.

Punchy valuations drive our downgrade to sell, said Kotak Institutional Equities, which has a target of Rs 1,075 for the stock from Rs 1,000 earlier. This is even as the brokerage has raised its FY2023-25E EPS estimates by 5-10 per cent on account of strong momentum in wedding demand and higher margin forecasts.Edelweiss has downgraded Vedant Fashions

The earnings before interest, tax, depreciation and ammortisation (EBITDA) was Rs 833 crore, a decline of 14.3% YoY. On QoQ, EBITDA rose 16.1%.The EBITDA margins for the quarter dropped 190 basis points to 20.5% in Q1FY23 compared to 24.3% in Q1FY22. On QoQIndia sales saw a drop of 6.5% YoY to Rs 1817 crore in Q1FY23. The formulation business dropped .